MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...
GlobalData on MSN1d
MAIA’s lung cancer therapy 99% more likely to improve OS over chemo aloneA treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...
New and positive data for Maia Biotechnology Inc.’s lead candidate for a particularly deadly and advanced lung cancer propelled the stock modestly higher on Feb. 4. The pivotal phase II THIO-101 study ...
CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...
Northern Tool + Equipment is bringing the high-octane excitement of Monster Jam® to the Little Rock community. On Thursday, February 20, customers will have the chance to experience the thrill-seeking ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on MAIA Biotechnology, Inc. (MAIA – Research Report), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback